Breaking News Instant updates and real-time market news.

TBPH

Theravance Biopharma

$22.18

-0.65 (-2.85%)

, GSK

GlaxoSmithKline

$39.85

-0.6 (-1.48%)

16:13
04/19/18
04/19
16:13
04/19/18
16:13

Theravance Biopharma reports publication of study of Treleggy Ellipta in COPD

Theravance Biopharma (TBPH) highlighted the publication in the New England Journal of Medicine of the landmark IMPACT study of Trelegy Ellipta in patients with chronic obstructive pulmonary disease. Trelegy Ellipta is the triple combination therapy of fluticasone furoate, umeclidinium, and vilanterol in a single Ellipta inhaler. Trelegy Ellipta is a product in which Theravance Biopharma has an economic interest in future payments that may be made by GlaxoSmithKline (GSK) or one of its affiliates pursuant to its agreements with Innovivam formerly Theravance, Inc. Theravance Biopharma is entitled to receive an 85% economic interest in the royalties paid by GSK on worldwide net sales. Those royalties are upward-tiering from 6.5% to 10%, resulting in cash flows to Theravance Biopharma of approximately 5.5% to 8.5% of worldwide net sales of Trelegy Ellipta. Results from additional secondary and other endpoints published in the NEJM include: a statistically significant 34% reduction in COPD hospitalizations for Trelegy compared to Anoro and a reduction of 13% compared to Relvar/Breo which was not statistically significant ; a 42.1% reduction in the risk of on-treatment all-cause mortality was observed for Trelegy compared to Anoro. The safety profile of single inhaler triple therapy was consistent with the safety profile of the individual components. Trelegy Ellipta is approved in Europe as a maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an ICS and a LABA. The product is also approved for use in the US for the long-term, once-daily, maintenance treatment of COPD patients who are receiving Breo and require additional bronchodilation or who are receiving Breo and Incruse. Regulatory applications for Trelegy Ellipta have been submitted and are undergoing assessments in a number of other countries.

TBPH

Theravance Biopharma

$22.18

-0.65 (-2.85%)

GSK

GlaxoSmithKline

$39.85

-0.6 (-1.48%)

  • 20

    Apr

  • 23

    Apr

  • 25

    Apr

  • 08

    May

  • 18

    May

  • 21

    May

  • 13

    Nov

TBPH Theravance Biopharma
$22.18

-0.65 (-2.85%)

05/10/17
LEER
05/10/17
NO CHANGE
Target $47
LEER
Outperform
Theravance Biopharma price target raised to $47 from $34 at Leerink
Leerink analyst Geoffrey Porges raised his price target Theravance Biopharma to $47 from $34 after the company reported Q1 financial results and provided an update for investors about its development progress and upcoming milestones. The analyst reiterates an Outperform rating on the shares.
06/16/17
CANT
06/16/17
INITIATION
Target $55
CANT
Overweight
Theravance Biopharma initiated with an Overweight at Cantor
Cantor Fitzgerald analyst Louise Chen started Theravance Biopharma with an Overweight rating and $55 price target.
08/16/17
EVER
08/16/17
INITIATION
Target $45
EVER
Outperform
Theravance Biopharma initiated with an Outperform at Evercore ISI
Evercore ISI analyst Josh Schimmer initiated Theravance Biopharma with an Outperform and a $45 price target.
03/29/18
PIPR
03/29/18
INITIATION
Target $45
PIPR
Overweight
Theravance Biopharma assumed with an Overweight at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren assumed coverage of Theravance Biopharma with an Overweight rating and $45 price target. The company's respiratory products Trelegy and revefenacin "provide solid valuation support with the potential for significant upside" from its proprietary 1473/JAK and 9855/nOH development candidate, the analyst contends. He has confidence in the Trelegy launch and revefenacin approval and recommends investors buy the shares.
GSK GlaxoSmithKline
$39.85

-0.6 (-1.48%)

03/22/18
MSCO
03/22/18
UPGRADE
MSCO
Equal Weight
GlaxoSmithKline upgraded to Equal Weight from Underweight at Morgan Stanley
Morgan Stanley analyst Vincent Meunier upgraded GlaxoSmithKline to Equal Weight and raised his price target for the shares to GBP 14 from GBP 13. The company's capital allocation strategy and operational repositioning show "clear signs of improvement," Meunier tells investors in a research note. Further, the analyst believes comments by the CEO suggest a large consumer deal is less likely than several months ago, which he believes reduces the risk of a dividend cut.
03/22/18
03/22/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. American Axle (AXL) and BorgWarner (BWA) were double-upgraded to Overweight from Underweight at Morgan Stanley. 2. GlaxoSmithKline (GSK) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Vincent Meunier saying the company's capital allocation strategy and operational repositioning show "clear signs of improvement." 3. General Mills (GIS) upgraded to Hold from Sell at Societe Generale with analyst Warren Ackerman citing valuation for the upgrade following yesterday's post-earnings selloff. 4. Pandora (P) upgraded to Strong Buy from Market Perform at Raymond James with analyst Justin Patterson saying AdsWizz will expand TAM by 2x to $28B, accelerate tech initiatives, materially expand reach, and could be worth approximately $4 per share. 5. Southwest (LUV) upgraded to Buy on valuation at Buckingham with analyst Daniel McKenzie saying shares are oversold and maintained a $70 price target. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/04/18
EXAN
04/04/18
UPGRADE
EXAN
Outperform
GlaxoSmithKline upgraded to Outperform from Neutral at Exane BNP Paribas
Exane BNP Paribas analyst Kerry Holford upgraded GlaxoSmithKline to Outperform with an increased price target of GBP 16.30.
04/04/18
04/04/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Transocean (RIG) upgraded to Buy from Hold at HSBC. 2. GlaxoSmithKline (GSK) upgraded to Outperform from Neutral at Exane BNP Paribas. 3. BHP Billiton (BHP) upgraded to Sector Perform from Underperform at RBC Capital and to Buy from Neutral at Citi. 4. Boston Beer (SAM) upgraded to Market Perform from Underperform at Cowen with analyst Vivien Azer citing strong Nielsen data in the non-beer category. 5. EnLink Midstream Partners (ENLK) upgraded to Overweight from Neutral at JPMorgan with analyst Jeremy Tonet saying he reduced his distribution growth expectations given the elevated cost of equity, but views the current 11.5% yield as sustainable. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

FCAU

Fiat Chrysler

$22.26

-0.205 (-0.91%)

08:58
05/25/18
05/25
08:58
05/25/18
08:58
Technical Analysis
Technical Take: Fiat Chrysler falls on 4.8M vehicle U.S.-market recall »

In pre-market trading the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BKE

The Buckle

$25.75

0.65 (2.59%)

08:55
05/25/18
05/25
08:55
05/25/18
08:55
Technical Analysis
Technical Take: The Buckle slides lower after reporting earnings »

In the pre-market the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

BAC

Bank of America

$30.19

-0.26 (-0.85%)

, PBR

Petrobras

$12.77

-2.335 (-15.46%)

08:55
05/25/18
05/25
08:55
05/25/18
08:55
Options
Notable open interest changes for May 25th »

Thursday's total…

BAC

Bank of America

$30.19

-0.26 (-0.85%)

PBR

Petrobras

$12.77

-2.335 (-15.46%)

AAPL

Apple

$188.18

-0.18 (-0.10%)

AFSI

AmTrust

$13.73

-0.045 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

ROST

Ross Stores

$82.95

0.35 (0.42%)

08:52
05/25/18
05/25
08:52
05/25/18
08:52
Technical Analysis
Technical Take: Ross Stores falls after earnings »

The shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPS

Gap

$32.97

1 (3.13%)

, FL

Foot Locker

$46.38

1.35 (3.00%)

08:52
05/25/18
05/25
08:52
05/25/18
08:52
Hot Stocks
On The Fly: Pre-market Movers »

HIGHER: Amarin (AMRN), up…

GPS

Gap

$32.97

1 (3.13%)

FL

Foot Locker

$46.38

1.35 (3.00%)

DECK

Deckers Brands

$103.63

0.8 (0.78%)

HIBB

Hibbett Sports

$28.95

0.6 (2.12%)

AMRN

Amarin

$3.04

0.04 (1.33%)

TEVA

Teva

$21.64

0.485 (2.29%)

BMRN

BioMarin

$88.30

-0.2 (-0.23%)

ZOES

Zoe's Kitchen

$14.48

-0.41 (-2.75%)

EGHT

8x8, Inc.

$22.00

0.35 (1.62%)

ADSK

Autodesk

$138.76

-0.54 (-0.39%)

SPLK

Splunk

$116.35

-0.2 (-0.17%)

CBB

Cincinnati Bell

$15.93

-0.225 (-1.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

  • 25

    May

  • 25

    May

  • 29

    May

  • 05

    Jun

  • 05

    Jun

  • 12

    Jun

  • 14

    Jun

  • 16

    Jun

  • 10

    Jul

  • 12

    Sep

LOMA

Loma Negra

$11.52

-1.47 (-11.32%)

08:51
05/25/18
05/25
08:51
05/25/18
08:51
Upgrade
Loma Negra rating change  »

Loma Negra upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOMA

Loma Negra

$11.52

-1.47 (-11.32%)

08:50
05/25/18
05/25
08:50
05/25/18
08:50
Hot Stocks
Loma Negra says not under investigation in Argentina for cartelization »

Loma Negra said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$272.87

-0.5 (-0.18%)

, SPX

S&P 500

$0.00

(0.00%)

08:49
05/25/18
05/25
08:49
05/25/18
08:49
General news
Trump says 'time will tell' after 'warm and productive' North Korean statement »

President Donald Trump…

SPY

SPDR S&P 500 ETF Trust

$272.87

-0.5 (-0.18%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLF

Herbalife Nutrition

$53.85

-0.14 (-0.26%)

08:47
05/25/18
05/25
08:47
05/25/18
08:47
Hot Stocks
Herbalife Nutrition announces preliminary results of self-tender offer »

Herbalife Nutrition…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$22.26

-0.205 (-0.91%)

08:46
05/25/18
05/25
08:46
05/25/18
08:46
Hot Stocks
Fiat Chrysler recalls estimated 4.8M U.S.-market vehicles for software upgrade »

FCA US announced it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:45
05/25/18
05/25
08:45
05/25/18
08:45
Conference/Events
Federal Reserve Chairman Powell participates in a panel discussion »

Federal Reserve Chairman…

NOK

Nokia

$6.09

-0.01 (-0.16%)

, AAOI

Applied Optoelectronics

$33.91

0.24 (0.71%)

08:45
05/25/18
05/25
08:45
05/25/18
08:45
Options
Largest borrow rate increases among liquid names »

Latest data shows the…

NOK

Nokia

$6.09

-0.01 (-0.16%)

AAOI

Applied Optoelectronics

$33.91

0.24 (0.71%)

MDXG

MiMedx

$8.86

-0.12 (-1.34%)

GERN

Geron

$4.81

0.14 (3.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

  • 19

    Jun

  • 20

    Jun

  • 25

    Jun

  • 26

    Jun

08:45
05/25/18
05/25
08:45
05/25/18
08:45
General news
Treasury Action: yields remained at low ebb »

Treasury Action: yields…

08:35
05/25/18
05/25
08:35
05/25/18
08:35
General news
U.S. durable goods orders fell 1.7% in April »

U.S. durable goods orders…

TIF

Tiffany

$126.44

0.3 (0.24%)

08:34
05/25/18
05/25
08:34
05/25/18
08:34
Recommendations
Tiffany analyst commentary  »

Tiffany price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 26

    Jun

DECK

Deckers Brands

$103.63

0.8 (0.78%)

08:34
05/25/18
05/25
08:34
05/25/18
08:34
Technical Analysis
Technical Take: Deckers at new 52-week high after earnings, analyst action »

The company reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USNA

USANA

$116.75

-2.85 (-2.38%)

08:34
05/25/18
05/25
08:34
05/25/18
08:34
Hot Stocks
USANA clinical sciences team to be led by Rolando Maddela, Jessie Johnson »

USANA is announcing a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WB

Weibo

$102.36

-1.08 (-1.04%)

08:33
05/25/18
05/25
08:33
05/25/18
08:33
Recommendations
Weibo analyst commentary  »

Weibo risk/reward…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

HWC

Hancock Whitney Corporation

$51.60

-0.2 (-0.39%)

, BBRG

Bravo Brio Restaurant

$4.05

(0.00%)

08:30
05/25/18
05/25
08:30
05/25/18
08:30
Options
One new option listing and two option delistings on May 25th »

New option listings for…

HWC

Hancock Whitney Corporation

$51.60

-0.2 (-0.39%)

BBRG

Bravo Brio Restaurant

$4.05

(0.00%)

HBHC

Symbol changed to HWC

$51.60

-0.2 (-0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:30
05/25/18
05/25
08:30
05/25/18
08:30
General news
Fed Chairman Powell will make an appearance »

Fed Chairman Powell will…

SPLK

Splunk

$116.35

-0.2 (-0.17%)

08:28
05/25/18
05/25
08:28
05/25/18
08:28
Recommendations
Splunk analyst commentary  »

Splunk price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

FL

Foot Locker

$46.38

1.35 (3.00%)

08:27
05/25/18
05/25
08:27
05/25/18
08:27
Technical Analysis
Technical Take: Foot Locker sharply higher after earning beat, outlook »

In pre-market trading the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

WAL

Western Alliance

$61.53

-0.305 (-0.49%)

, FCB

FCB Financial

$61.60

0.2 (0.33%)

08:26
05/25/18
05/25
08:26
05/25/18
08:26
Recommendations
Western Alliance, FCB Financial analyst commentary  »

Western Alliance unlikely…

WAL

Western Alliance

$61.53

-0.305 (-0.49%)

FCB

FCB Financial

$61.60

0.2 (0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LH

LabCorp

$175.31

-0.27 (-0.15%)

, DGX

Quest Diagnostics

$100.89

-0.34 (-0.34%)

08:25
05/25/18
05/25
08:25
05/25/18
08:25
Recommendations
LabCorp, Quest Diagnostics, UnitedHealth, Aetna analyst commentary  »

UnitedHealth news…

LH

LabCorp

$175.31

-0.27 (-0.15%)

DGX

Quest Diagnostics

$100.89

-0.34 (-0.34%)

UNH

UnitedHealth

$242.73

-1.48 (-0.61%)

AET

Aetna

$177.05

-0.31 (-0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 12

    Jun

ZOES

Zoe's Kitchen

$14.48

-0.41 (-2.75%)

08:21
05/25/18
05/25
08:21
05/25/18
08:21
Downgrade
Zoe's Kitchen rating change  »

Zoe's Kitchen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.